ArticleFrontiers in pharmacology2020
Spontaneous Reports of Serious Adverse Drug Reactions Resulting From Drug-Drug Interactions: An Analysis From the French Pharmacovigilance Database.
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- High-throughput signal detection of hepatotoxic drug-drug interactions in hospitalized elderly patients: an NLP-driven pharmacovigilance study.Annals of medicine · 2026Article
- Machine learning and deep learning-based drug-drug interactions prediction: a systematic review focused on anticancer drugs.NPJ precision oncology · 2026Article
- Analysis of drug-drug interactions between psychiatric drugs in spontaneous adverse drug reaction reports from EudraVigilance.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- A Two-Year Pharmacovigilance Analysis of Adverse Drug Reactions Reported from a University Allergy Setting.Journal of clinical medicine · 2026Article
- Closing the loop: human-augmented, mechanistically enhanced AI for proactive management of drug-drug interactions.Frontiers in pharmacology · 2026Article
- Analysis of drug-drug interactions in spontaneous adverse drug reaction reports from EudraVigilance focusing on psychiatric drugs and somatic medication.BMC psychiatry · 2025Article
- Prescription patterns of comedications associated with drug-drug interactions risk in HCV-infected patients undergoing direct-acting antiviral treatment: an analysis of an administrative claims database in Japan.Journal of pharmaceutical health care and sciences · 2025Article
- Potential inappropriate medications and drug-drug interactions in adverse drug reactions in the elderly: a retrospective study in a pharmacovigilance database.Frontiers in pharmacology · 2025Article
- Epidemiology of reported serious adverse drug reactions due to anti-infectives using nationwide database of Thailand.PloS one · 2025Article
- Thinking Three-Dimensionally: A Self- and Externally-Controlled Approach to Screening for Drug-Drug-Drug Interactions Among High-Risk Populations.Clinical pharmacology and therapeutics · 2024Article
- Prevalence and differences in the co-administration of drugs known to interact: an analysis of three distinct and large populations.BMC medicine · 2024Article
- Spontaneous adverse drug reactions reported in a thirteen-year pharmacovigilance program in a tertiary university hospital.Frontiers in pharmacology · 2024Article
- Clinical significance of potential drug-drug interactions in older adults with psychiatric disorders: a retrospective study.BMC psychiatry · 2022Article
- A Standardized Dataset of a Spontaneous Adverse Event Reporting System.Healthcare (Basel, Switzerland) · 2022Article
- Adverse drug reactions and correlations with drug-drug interactions: A retrospective study of reports from 2011 to 2020.Frontiers in pharmacology · 2022Article
- Opioid Drug-Drug-Drug Interactions and Unintentional Traumatic Injury: Screening to Detect Three-Way Drug Interaction Signals.Frontiers in pharmacology · 2022Article
- Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments.International journal of environmental research and public health · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Few data are available on the clinical impact of drug-drug interactions (DDIs). Most of the studies are limited to the analysis of exposure to potential DDI or the targeted impact of the combination of a few drugs or therapeutic classes. The analysis of adverse drug reaction (ADR) reports could be a mean to study generally the adverse effects identified due to a DDI. Our objective was to describe the characteristics of ADRs resulting from DDIs reported to the French Pharmacovigilance system and to identify the drugs most often implicated in these ADRs. Considering all ADR reports from January 01, 2012, to December 31, 2016, we identified all cases of ADR resulting from a DDI (DDI-ADRs). We then described these in terms of patients' characteristics, ADR seriousness, drugs involved (two or more per case), and ADR type. Of the 4,027 reports relating to DDI-ADRs, 3,303 were related to serious ADRs. Patients with serious DDI-ADRs had a median age of 76 years (interquartile range: 63-84); 53% were male. Of all serious DDI-ADRs, 11% were life-threatening and 8% fatal. In 36% of cases, the DDI causing the ADR involved at least three drugs. Overall, 8,424 different drugs were mentioned in the 3,303 serious DDI-ADRs considered. Altogether, drugs from the "antithrombotic agents" subgroup were incriminated in 34% of serious DDI-ADRs. Antidepressants were the second most represented therapeutic/pharmacological subgroup (5% of serious DDI-ADRs). Among the 3,843 ADR types reported in the 3,303 serious DDI-ADRs considered, the most frequently represented were hemorrhage (40% clinical hemorrhage; 6% biological hemorrhage), renal failure (8%), pharmacokinetic alteration (5%), and cardiac arrhythmias (4%). Hemorrhagic accidents are still an important part of serious ADRs resulting from DDIs reported in France. The other clinical consequences of DDIs seem less well identified by pharmacovigilance. Moreover, more than one-third of serious DDI-ADRs involved at least three drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.